Treatment failure 5 days [clinicaltrials_resource:23aaf61d4323781826cdac897974cd4c]
The primary endpoint was treatment failure, defined as the occurrence of any of the following within a period of 120 h (5 days) from the time of admission: (i) Fresh hematemesis ≥2 hr after EVL; or (ii) Death within 5 days.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Treatment failure 5 days [clinicaltrials_resource:23aaf61d4323781826cdac897974cd4c]
The primary endpoint was treatment failure, defined as the occurrence of any of the following within a period of 120 h (5 days) from the time of admission: (i) Fresh hematemesis ≥2 hr after EVL; or (ii) Death within 5 days.
Bio2RDF identifier
23aaf61d4323781826cdac897974cd4c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:23aaf61d4323781826cdac897974cd4c
measure [clinicaltrials_vocabulary:measure]
Treatment failure
time frame [clinicaltrials_vocabulary:time-frame]
description
The primary endpoint was treat ...... ; or (ii) Death within 5 days.
identifier
clinicaltrials_resource:23aaf61d4323781826cdac897974cd4c
title
Treatment failure 5 days
@en
type
label
Treatment failure 5 days [clinicaltrials_resource:23aaf61d4323781826cdac897974cd4c]
@en